A/Prof David Ziegler
MBBS UNSW, MD/PhD UNSW, Dip Paed, FRACP
Dr David Ziegler is the National Trial Study Chair of the Zero Childhood Cancer program.
He is a paediatric oncologist, haematologist and bone marrow transplant physician at the Kids Cancer Centre, Sydney Children’s Hospital, Randwick, with expertise in neuro-oncology. He cares for children with benign and malignant brain tumours.
Dr Ziegler is a conjoint associate professor at UNSW. He leads the Targeted Therapy Group at Children’s Cancer Institute, where his preclinical research focuses on novel therapies for childhood brain tumours, in particular the most malignant of all paediatric tumours—Diffuse Intrinsic Pontine Glioma (DIPG). He has established a national tumour bank for DIPG tumours, and employed robotic high-throughput screening technology to discover new treatment strategies for this devastating disease.
Dr Ziegler’s clinical research focuses on translating discoveries from the laboratory to the clinic. He heads the Clinical Trials Program at the Kids Cancer Centre, and has established an early phase clinical trial program to offer new treatments for children with relapsed or refractory disease. He chairs a national study for children with relapsed neuroblastoma, and is developing further trials for children with neuroblastoma, leukaemia, and brain tumours.
Dr Ziegler completed his clinical training in paediatric haematology/oncology at Sydney Children’s Hospital. From 2005–2007 he was a Fulbright Scholar at the Dana-Farber Cancer Institute, Harvard Medical School and Children’s Hospital Boston. His research focused on the preclinical development and clinical translation of novel therapies for paediatric brain tumours.